Gentian Diagnostics ASA
Develops and markets in vitro diagnostic reagents for human and veterinary use.
GENT | OL
Overview
Corporate Details
- ISIN(s):
- NO0010748866
- LEI:
- 5967007LIEEXZXHNM861
- Country:
- Norway
- Address:
- Bjørnåsveien 5, 1596 Moss
- Website:
- https://www.gentian.com/
- Sector:
- Manufacturing
Description
Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-05-24 09:30 |
Notice of annual general meeting
|
English | 366 bytes | ||
| 2018-05-15 20:33 |
2017 Annual Report
|
English | 2.9 MB | ||
| 2018-05-15 20:33 |
2017 Annual Report
|
English | 796 bytes | ||
| 2018-05-15 05:15 |
First Quarter Financial Report
|
English | 1.4 MB | ||
| 2018-05-15 05:15 |
First Quarter Financial Report
|
English | 1.0 KB | ||
| 2018-05-14 19:57 |
Share option program and compensation policy
|
English | 322.4 KB | ||
| 2018-05-14 19:57 |
Share option program and compensation policy
|
English | 1.6 KB | ||
| 2018-04-11 05:30 |
GENTIAN ACHIEVES PROOF OF CONCEPT ON WHOLE BLOOD HEMOGLOBIN WITH FERRITIN
|
English | 121.4 KB | ||
| 2018-04-11 05:30 |
GENTIAN ACHIEVES PROOF OF CONCEPT ON WHOLE BLOOD HEMOGLOBIN WITH FERRITIN
|
English | 2.1 KB | ||
| 2018-02-27 06:00 |
4Q 2017 Results and preliminary annualreport
|
English | 659.7 KB | ||
| 2018-02-27 06:00 |
4Q 2017 Results and preliminary annualreport
|
English | 1.0 KB | ||
| 2017-12-05 07:46 |
Flagging
|
English | 824 bytes | ||
| 2017-12-04 10:20 |
Gentian Diagnostics appoints Njaal Kind as Group CFO
|
English | 2.7 KB | ||
| 2017-12-04 09:43 |
Financial calendar
|
English | 614 bytes | ||
| 2017-11-15 06:17 |
Third Quarter Financial Report
|
English | 566.9 KB |
Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gentian Diagnostics ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
